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School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom
V(D)J recombination generates antigen receptor diversity by mixing and matching
individual variable (V), diversity (D), and joining (J) gene segments. An obligate by-product
of many of these reactions is the excised signal circle (ESC), generated by excision of
the DNA from between the gene segments. Initially, the ESC was believed to be inert
and formed to protect the genome from reactive broken DNA ends but more recent
work suggests that the ESC poses a substantial threat to genome stability. Crucially,
the recombinase re-binds to the ESC, which can result in it being re-integrated back
into the genome, to cause potentially oncogenic insertion events. In addition, very
recently, the ESC/recombinase complex was found to catalyze breaks at recombination
signal sequences (RSSs) throughout the genome, via a “cut-and-run” mechanism.
Remarkably, the ESC/recombinase complex triggers these breaks at key leukemia driver
genes, implying that this reaction could be a significant cause of lymphocyte genome
instability. Here, we explore these alternate pathways and discuss their relative dangers
to lymphocyte genome stability.
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INTRODUCTION
V(D)J recombination is essential to generate a diverse adaptive immune system that can respond
to vast numbers of potential pathogens. This is achieved, in part, from the unique arrangement
of antigen receptor loci where multiple copies of variable (V), diversity (D), and joining (J)
gene segments lie upstream of constant exon(s). During V(D)J recombination, one of each V, D
(if present), and J gene segments are somatically recombined at random to generate the variable
exon of the antigen receptor. The stochastic selection of gene segments, along with their imprecise
joining enables production of a highly diverse antigen receptor repertoire (1).
The products of the lymphoid specific recombination activating genes 1 and 2 (RAG1 andRAG2)
(2), are essential for V(D)J recombination (3, 4). These proteins recognize recombination signal
sequences (RSSs) that flank each V, D, and J gene segment and consist of a conserved heptamer
(CACAGTG) and nonamer (ACAAAAACC), separated by non-conserved “spacers” of either 12
± 1 or 23 ± 1 bp. Importantly, efficient recombination only occurs between RSSs with dissimilar
spacers, the “12/23 rule” (5).
V(D)J recombination can be divided into cleavage and joining phases [Figure 1; (6)]. Cleavage
is initiated when a hetero-tetrameric complex of RAG1 and RAG2 assembles on either a 12- or
23-RSS (7) and subsequently captures a complementary RSS. Upon formation of a stable synaptic
complex, the DNA is unwound at the 5’ end of the heptamer (8), followed by introduction of a
single-strand DNA nick at the heptamer-coding sequence boundary by the DDE catalytic motif of
RAG1 (9–11). The exposed free 3’ hydroxyl group then attacks the opposite DNA strand in a direct
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FIGURE 1 | Overview of the cleavage and joining phases of V(D)J recombination. The cleavage phase begins when a RAG1 + RAG2 hetero-tetrameric complex (blue
oval) binds to either a 12-RSS (filled triangle) or 23-RSS (open triangle), with the consensus sequences shown. This complex then synapses with a partner RSS of the
complementary spacer length. The RAG complex subsequently nicks one DNA strand of each RSS and catalyzes the hydrophilic attack by the resulting hydroxyl
group onto the other DNA strand in a direct trans-esterification reaction, to generate hairpinned coding ends and blunt signal ends. Both the coding and signal ends
are repaired by the NHEJ machinery, although coding ends are often imprecisely repaired to increase diversity, as indicated by red nuclotides. The signal ends remain
bound to the RAG proteins until RAG expression is downregulated; subsequent ligation of the signal ends forms a signal joint (SJ) and results in the generation of an
episomal circle, the excised signal circle (ESC). In humans, these range from 655 bp (at the TCRB locus) to ∼1Mb (at the IgH locus).
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trans-esterification reaction (2), yielding a pair of covalently
sealed hairpins at the coding ends, and blunt signal ends (1).
Repair of the four broken DNA ends is achieved by the non-
homologous end joining (NHEJ) machinery (12). Whilst the
coding ends undergo extensive processing, resulting in addition
or deletion of bases to increase antigen receptor gene diversity,
the RSSs at the signal ends are precisely joined in a head-to-
head arrangement, generating a signal joint (SJ). Usually, V(D)J
recombination deletes the DNA between the gene segments, to
generate an excised signal circle [ESC; (1)] that is covalently
sealed at the SJ (Figure 1). However, recombination, primarily
of the Igκ locus, can result in inversion of the intervening DNA
and retention of the SJ in the genome. Notably, production
of every functional antigen receptor gene generates at least
one, and up to 10 ESCs, depending on the level of non-
productive rearrangement.
The ESC is a non-replicative episome which is likely lost
during cell division. Nonetheless, it persists in chicken T cells
for approximately 2 weeks (13) and in primates, this appears
to be substantially longer (14). Little to no ESC degradation
has been observed and both T cell receptor excision circles
(TRECs) and KRECs, generated by recombination to the kappa
deleting element during allelic and isotypic exclusion, have
proved to be excellent markers of recently generated T- and B-
cells, respectively, with 70% of newly produced T cells and 50%
of transitional and naïve B cells testing positive (15, 16).
Due to their lack of coding capacity and eventual loss from
the cell, it is reasonable to ask why cells bother to generate
ESCs. One possibility is that SJ formation is required to maintain
chromosome integrity during inversional recombination and this
mechanism is simply retained during deletional recombination.
Generation of a circle during deletional recombination has
the further advantage of sequestering potentially reactive
DNA ends. Recent studies strongly suggest, however, that far
from being inert, ESCs are crucial constituents of reactions
that have potentially devastating consequences for lymphocyte
genome stability.
RAG MEDIATED SIGNAL END
TRANSPOSITION
The first inkling that the ESC poses a potential threat stemmed
from the remarkable similarity between the core domain of
RAG1, including the catalytic DDE motif, and the Transib
family of transposes (17). Furthermore, ProtoRAG, a recently
discovered transposon in lancelets, is comprised of both RAG1-
and RAG2-like genes, flanked by terminal inverted repeats
(TIRs), similar to RSSs. This strongly implies that the RAG
recombinase evolved from an ancient transposase that was
acquired into the jawed vertebrate genome by horizontal gene
transfer (18).
Transposases recognize short sequences surrounding the
transposon and introduce double strand breaks (DSBs) between
these recognition sequences and the flanking chromosomal
DNA, in much the same way as the V(D)J recombinase
recognizes RSSs (19). The initial breakage of DNA at the antigen
receptor loci and the hairpin end structures formed is also
analogous to the process by which hAT family transposons are
excised from their host genome (20). Furthermore, RSSs resemble
inverted repeats found at either end of a transposon and RAG
proteins remain associated with RSSs after DNA cleavage, which
is also common in transposition reactions (21). Consequently,
it was not surprising that RAG proteins were found to mediate
signal end transposition, at least in vitro.
Indeed, both the Gellert and Schatz laboratories demonstrated
that in the presence of RAG proteins, DNA substrates flanked by
a pair of dissimilar RSSs undergo an intermolecular transposition
reaction into DNA targets [Figure 2A; (23, 24)]. Furthermore,
the SJs were shown to be opened by a “nick-nick” reaction,
whereby RAGs sequentially nick at the heptamer-heptamer
junction on each strand, to generate the OH− groups required
to attack the target DNA during transposition (25).
Despite clear evidence for RAG-mediated transposition events
in vitro, the impact of these events on genomic stability
appears inconsequential. Only two natural integration events
have been described (26); in each case, an excised signal
end fragment from the TCRα locus was integrated into
the HPRT (hypoxanthine phosphoribosyltransferase) locus in
human T cells. Although a handful of transposition events
have been observed experimentally, characterized by a 5 bp
duplication at the insertion site (27), no single documented case
of leukemia or lymphoma can be traced to a transposition event.
Themost likely explanation is the suppression of transposition by
the RAG2 C-terminus (28): Full length RAG2 does not support
efficient transposition (29), in contrast to “core” RAG2 (amino
acids 1–387), commonly used in vitro. This suppression appears
to be achieved by the RAG2 C-terminal domain stabilizing
the cleaved signal complex (30), to prevent subsequent capture
and transposition of signal ends. Consequently, transposition
reactions are almost completely suppressed in vivo.
RAG MEDIATED ESC RE-INTEGRATION
Although signal ends are not efficiently transposed into the
genome, ESCs can be readily cleaved (25) and re-bound by RAG
proteins (31) in vivo. As a potential consequence, the ESC has
been found to undergo relatively efficient re-integration into the
genome at RSSs and cryptic RSSs (cRSSs), i.e., RSSs outside the
antigen receptor loci that resemble consensus RSSs, via a trans-
V(D)J recombination reaction. Indeed, in an ex vivo assay, Nadel
et al. observed that RAGs can integrate genuine SJ sequences into
12-RSS target substrates via synapsis with the 23-RSS of the SJ
(32). This generates a new SJ and a pseudo-hybrid joint, where
the RSS is joined to a coding end (Figure 2B). Consistent with
bona fide trans-V(D)J recombination, the re-integration reaction
usually does not violate the 12/23 rule (32) and depends on
Artemis to open the hairpin at the coding end. Furthermore,
pseudo-hybrid joints, with characteristic processing of the coding
end, are observed in mouse thymocytes (32).
A genome wide screen of signal end sequences in precursor
T-cells, similarly confirmed the presence of ESC insertions in
vivo. Approximately half were due to re-integration of an ESC,
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FIGURE 2 | Three pathways by which a RAG/SJ complex can lead to genomic instability. (A) During RAG mediated signal end transposition, the free hydroxyl groups
of the signal ends are used by the RAG proteins (blue oval) in a direct trans-esterification reaction to attack target DNA. DNA polymerase repairs the gaps that are
generated, to produce a 4–5 bp repeat of DNA flanking the insertion (red dotted lines). (B) Re-integration of an ESC into a genomic RSS. The SJ forms a synaptic
complex with a genomic RSS (blue triangle). RAG proteins cleave both the SJ and RSS in a trans-V(D)J recombination reaction. End repair by the non-homologous
end joining machinery results in the formation of a chromosomal signal joint and a pseudo-hybrid joint, which typically has imprecise end processing. (C) Cut-and-run.
The SJ forms a synaptic complex with a genomic RSS (blue triangle). This results in cutting of the genomic RSS but not the SJ, most likely because RAG complexes
(blue ovals) bind to each RSS of the SJ and block its cutting. The cleaved RSS is released from the SJ/RSS complex, but the RAG/ESC complex remains intact to
potentially generate further DSBs at other genomic RSSs. In some instances, it is possible that RAGs nick the SJ which may make it easier for the RAG-SJ complex
to capture a partner RSS. Since consensus RSSs were used in the published work (22), the cut-and-run mechanism could potentially occur with ESCs from all
antigen receptor loci, although the frequency of consensus RSSs is higher at immunoglobulin loci.
with a distinct absence of transposition events (33), suggesting
that re-integration is the principal mechanism of ESC insertion.
A high rate of ESC re-integration was also observed using
episomes carrying LMO2 and TAL2 cRSSs (32), implying that
re-integration at proto-oncogenes is feasible. Given that ESCs
are highly likely to carry promoters, such as those adjacent to V
gene segments, such re-integration could upregulate oncogenes,
contributing to malignant transformation. Notably, the RAG2
C-terminus also suppresses ESC re-integration by about 7-fold
(33). This may relate to the degradation of RAG2 outside of
G1 by phosphorylation of threonine 490 (34), which has been
shown to suppress genome instability (35). Nevertheless, based
on the experiments described above, ESC re-integration has been
estimated to occur in 1 in 1,000,000 to 1 in 10,000 thymocytes
(32, 33). Given that millions of lymphocytes are generated each
day, this is equivalent to∼5,000 re-integration events per genome
per day (32).
Despite the high estimated number of re-integration events,
none has been unequivocally linked tomalignant transformation.
Moreover, only one natural re-integration has been reported,
where a TCRα-derived ESC was inserted into a cRSS in the
HPRT locus (36). The large discrepancy between the estimated
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re-integration frequency and actual carcinogenic events begs the
question of why more disease-causing re-integrations are not
observed. One possibility is that re-integration results in B- or
T- cell death, either by insertional mutagenesis into critical genes
or because re-integration of an ESC, which can be up to 1Mb in
humans, is error-prone and generates DSBs that trigger apoptosis
via the p53 surveillance pathway. A second possibility is that re-
insertion occurs, but is not detected (32). Since recombination
is stochastic, it is difficult to predict which ESCs will be
generated, and moreover, the ESC could be potentially inserted
at any of 10 million cRSSs (37), which makes screening for
reintegration difficult. Indeed, over a decade after re-integration
was first described, its contribution to lymphoid malignancies
remains unknown.
Although not strictly involving ESCs, the Robbiani laboratory
recently described a related mechanism of RAG-mediated
genome instability (38). Using bespoke translocation capture
(TC-seq) and insertion capture sequencing (IC-seq), they found
that RAGs can release DNA fragments (with signal ends, coding
ends or hybrid ends) from antigen receptor loci, independent of
normal recombination, and these fragments reintegrate into a
RAG-independent DSB elsewhere in the genome. By developing
a novel pipeline to analyse whole genome sequencing data,
they found 5 out of 34 acute lymphoblastic leukemia (ALL)
and follicular lymphoma patients displayed genomic insertions
from the antigen receptor loci. However, the authors believe
this is an underestimate due to limitations in sequencing
depth and read lengths. Notably, with such improvements in
whole-genome sequencing, this analysis pipeline could be used
additionally to detect RAG-mediated ESC re-integration in
lymphoid malignancies.
CUT-AND-RUN
Whilst re-integration events clearly occur, it was shown recently
that synaptic complex formation between an ESC and RSS in vitro
results in efficient RSS cleavage, whereas the ESC itself is barely
cut (22). This asymmetric cleavage of an ESC/RSS complex does
not appear to be an in vitro artifact as assays using a cell line
derived from an ALL patient, showed that episomes carrying a
12- or 23-RSS are also cleaved readily whereas substrates bearing
a SJ (ESC) exhibit negligible cutting (22).
This phenomenon can be best explained by RAGs binding
to both RSSs of the ESC (22), thereby occluding the heptamer-
heptamer boundary of the SJ, preventing its cleavage. What
makes this reaction particularly dangerous is following cleavage,
the broken RSS is released, generating a DSB (22) whereas the
ESC/RAG complex remains intact. Although not yet observed
directly, hypothetically, the RAG/ESC complex could catalyze
further breaks at new cRSSs in a reaction termed “cut-and-run”
(Figure 2C). This reaction could potentially continue until the
RAG proteins are downregulated and/or the ESC is eventually
cleaved—with disastrous consequences for the lymphocyte
genome. Indeed, analysis of chromosome breakpoints caused
by the RAG/ESC complex, using linear amplification-mediated,
high-throughput genome-wide sequencing [LAM-HTGTS; (39)]
showed a significant overlap between cut-and-run-mediated
breakpoints and those observed in ETV6/RUNX1-positive ALL
patients (22, 40). Moreover, breakpoints in eight out of the eleven
most commonly mutated genes in B-cell ALL were observed in
the presence of the ESC (22). This strongly implies that cut-and-
run has a role in the development of ETV6/RUNX1-positive ALL,
and potentially other lymphoid cancers.
THE DANGERS OF CUT-AND-RUN
COMPARED TO RE-INTEGRATION
The discovery of two distinct mechanisms by which the ESC
triggers genome instability raises the fundamental question of
which poses the greater danger. This will be influenced by both
the reaction frequency and damage caused by each reaction.
Reaction Frequency
The overall reaction frequency will depend on its actual
frequency as well as the availability of reaction components.
Both re-integration and cut-and-run require a complex between
RAGs and the ESC and thus will be restricted to cells where
both are present, such as pro- and pre-B cells as well as
immature B cells, where RAGs are upregulated for receptor
editing and receptor revision (41, 42). Moreover, whilst re-
integration can theoretically occur with either a covalently closed
ESC or open SJ, cut-and-run requires the ESC to be covalently
closed. Notably, SJs remain unligated following recombination
until RAGs are down-regulated, either as a result of cell
replication (34, 43) or following productive antigen receptor
recombination (44). This will therefore further restrict cut-and-
run; nonetheless, it could occur in normal lymphocytes, for
example, by using ESCs in pre-B cells that were generated by
IgH recombination in pro-B cells. Substrates for both reactions
are likely to be substantially increased, however, in cancer cells.
Indeed, a number of pre-leukaemic (45) and leukaemic cells (46)
continually express RAGs, triggering ongoing recombination
and increased production of ESCs (47). Because these cells
continually divide, the generation of covalently closed ESCs is
likely to be particularly high, thereby enhancing the risks of
further genome instability.
Nonetheless, the window in which cut-and-run or
re-integration can occur will be restricted by the short half-
life of RAG1 [∼15–30min; (48, 49)] and by the cell-cycle
dependent degradation of RAG2 outside of G1 (34, 35). Not
only this, but it appears that the lymphocyte genome has
tried to protect itself against off-target RAG cleavage: Only
∼3500 of the millions of cRSSs are occupied by RAG1 (50),
substantially limiting where breaks could occur. In addition,
genomic regions outside of the antigen receptor loci that are
enriched for RAG binding were found to be depleted of RSSs, a
mechanism suggested to protect active transcriptional start sites
from off-target RAG cleavage (50).
Yet further restrictions on RSS cleavage are imposed by local
chromatin modifications. Indeed, RSSs need to be accessible to
RAGs and to have proximal nucleosomes marked by acetylation
of lysine 27 of H3 (H3K27Ac) for RAG1 binding (51) and
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trimethylation of lysine 4 of H3 (H3K4me3) for RAG2 (52, 53).
Whilst these factors undoubtedly provide some protection,
cleavage at cRSSs clearly still occurs. Indeed, breaks at cRSSs in
cancer driver genes were found to be a predominant cause for
cancer progression in ETV6/RUNX1ALL, and our LAM-HTGTS
experiments suggest the ESC could play a role in causing some of
these breaks (22, 40).
Interaction of RAG2 with H3K4me3 via its PHD finger
has a further regulatory role, namely to overcome the auto-
inhibition of RAG1 cleavage, imposed by RAG2 (54–56). Since
the chromatin modifications present on ESCs are currently
unknown, it is difficult to determine if the ESC/RAG complex
is affected by altered H3K4me3 levels. Nonetheless, formation of
the RAG/ESC complex generates half of the synaptic complex
required for either cut-and-run or re-integration, meaning
that these reactions require just one accessible cRSS in the
genome (22). This, together with the intrinsic mobility of the
RAG/ESC complex, is expected to increase the chances of
the RAG/ESC complex “finding” genomic (c)RSSs with the
correct chromatin modifications. Furthermore, RAG proteins
have been shown to nick the ESC in vitro and in vivo
(25), which could also increase the chances of the RAG/ESC
complex capturing a partner RSS, although the level of ESC
nicking that we observed was noticeably lower than at an
RSS (22).
Considering the reaction rate, cut-and-run is far more likely
to occur. In fact, in vitro reactions suggest there is a 10-
fold greater likelihood of cutting just at the RSS (for cut-
and-run) compared to cutting at both the RSS and ESC
(22), to enable re-integration. Furthermore, the fact that the
ESC/recombinase complex remains intact following cutting at
one site (22) means that cut-and-run could potentially trigger
a series of DSBs, resulting in significant damage. By contrast,
re-integration if it occurs, is very likely to occur only once as
the event typically mutates one of the RSSs (32), preventing
further reactivity. Whilst it is difficult to know the actual
frequency of cut-and-run, using γH2AX as a marker for DSB,
physiological levels of RAGs (57) and close to physiological
levels of ESCs (3–6 ESCs per cell), an average of two additional
DSBs were observed in ∼20% of cells in the presence of
the ESC, compared to control cells (22). This is considerably
higher than the estimates for re-integration of 1 in 100,000
cells (33), suggesting that cut-and-run could be both frequent
and dangerous.
Damage Caused by Cut-and-Run or
Re-integration
Both re-integration of the ESC and the cut-and-run reaction
pose significant threats to genomic stability but theoretically,
a single ESC re-integration event has the potential to cause
a greater degree of genomic disruption due to the insertion
of up to 1Mb of DNA. Furthermore, due to the presence of
strong promoters within the antigen receptor loci, re-integration
of an ESC could upregulate genes next to the insertion
site, including proto-oncogenes such as LMO2. Not only
this, but Nadel et al. observed two cases of translocations
which appeared to be associated with insertion events (32),
suggesting secondary re-arrangement events may occur
after integration.
A single cut-and-run event has, in theory, a lower probability
of genomic disruption compared to ESC re-integration. However,
the damage caused will depend entirely on the processing
of the break. Asymmetric ESC/RSS cleavage generates one
hairpinned and one blunt end (22); crucially, these broken ends
are released and are not chaperoned by RAGs to the NHEJ
machinery (58). Although it is possible that the NHEJ proteins
are recruited independently, resulting in hairpin opening and
repaired DNA that closely resembles the sequence prior to
cleavage [akin to open and shut joints; (59)], it is also
possible that the released ends are processed by the error-prone
alternative NHEJ pathway or that they may be used as substrates
for chromosome translocations. Indeed, DSBs generated by
cut-and-run were found to readily undergo translocation, as
determined by the LAM-HTGTS assay (22, 39). Moreover, one
of the most common V(D)J recombination errors is the end
donation reaction, where a broken RSS becomes joined with
an independently broken DNA end (19). It is possible that
some of the breaks generated by cut-and-run are substrates for
such reactions.
Relationship to Development of Cancer
The relative dangers of these reactions can be further estimated
by considering their links to cancer. To date, no documented
examples exist of cancers triggered by re-integration. This
may be because re-integration is hard to detect and it was
argued that since approximately one third of T-ALL cases
have oncogene activation without abnormal karyotypes (32),
oncogenesis triggered by pathways such as re-integration may
be involved. However, many whole genome sequences from
patients have since become available, which show relatively small
chromosome changes that would not be detected karyotypically
but nonetheless lead to oncogene activation. Crucially, many
of these small changes in ETV6/RUNX1-positive ALL occur at
RSSs (40) and there is a strong correlation between the breaks in
patients and those caused by cut-and-run (22, 40). Furthermore,
about half of the chromosome abnormalities mapped via whole
genome sequencing show breaks at just one RSS (40). It is difficult
to account for such breaks during normal V(D)J recombination
given the stringency for coupled RSS cleavage and end joining.
Cut-and-run could account for such breaks.
CONCLUDING STATEMENT
It is clear that the ESC is far from inert but instead poses a
significant threat to genome stability. Although re-integration
has the potential for significantly greater damage, its low
frequency compared to cut-and-run and the low probability of
integrating at a proto-oncogene significantly reduces its overall
danger. Cut-and-run, on the other hand, appears to be frequent
and could be a source of breaks for the major chromosome
alterations associated with errors in V(D)J recombination.
However, to fully understand the impact of cut-and-run, further
experiments are required to determine (a) the outcomes of the
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released broken ends, (b) if the ESC “runs” to trigger subsequent
genomic breaks, and (c) if cut-and-run contributes to other B and
T cell cancers.
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